Moonlake Immunotherapeutics (MLTX)

$15.37 -0.42 (-2.66%)
Market Cap 1.01B
Revenue (ttm) 0.00
Net Income (ttm) -118.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.25
Volume 1,071,600
Avg Vol 2,456,272
Day's Range N/A - N/A
Shares Out 64.23M
Stochastic %K 36%
Beta 1.21
Analysts Sell
Price Target $20.28

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
JT4CashMoney
JT4CashMoney Feb. 4 at 1:44 AM
$MLTX just saw this new positive article in MoonLake: https://www.marketbeat.com/originals/biotech-breakout-moonlake-up-30-on-fda-wins/#google_vignette
2 · Reply
GEEK102
GEEK102 Feb. 4 at 1:37 AM
$MLTX might cash out and throw it on open
0 · Reply
Bigpapa46
Bigpapa46 Feb. 4 at 12:20 AM
$MLTX EHSF in Malta runs Feb 4–6, and MoonLake will be presenting several HS talks and posters during the conference. Sessions usually start around 8:30am Malta time, which is about 2:30am Eastern / 11:30pm Pacific (the night before), so any updates will show up very early in the U.S. It’s a medical conference where top HS doctors and specialists see and discuss the data. How they react matters, because these are the people who actually decide how new treatments get used in the real world. So tonight at 11:30pm pacific it kicks off!
0 · Reply
JoeBio
JoeBio Feb. 4 at 12:05 AM
$MLTX MoonLake has not announced any public release date for 48‑week VELA data, but based on the trial timelines and the Week‑16 readout (September 2025), the earliest realistic window for 48‑week data is mid‑to‑late 2026, with the most likely timing around Q3 2026. This is because the VELA trials follow a fixed 52‑week treatment period, and companies typically need several months after the last patient visit to clean, lock, and analyze long‑term data.
0 · Reply
Doomsayer1000
Doomsayer1000 Feb. 3 at 11:43 PM
$MLTX bulls don’t what they’re holding. $14 incoming
1 · Reply
Bigpapa46
Bigpapa46 Feb. 3 at 11:06 PM
$MLTX Bigbadjohn89- AI knows mine as well!
1 · Reply
Modern_portholio_theory
Modern_portholio_theory Feb. 3 at 10:58 PM
$MLTX been tracking available shares which can be borrowed on IBKR...tells an interesting picture right now- appears significantly less people are willling to lend out their shares. what does this mean ? I can only suspect it means certain larger holders are not willing to lend out, for optimistic reasons - I would not want an issue with a shortie having a 'failure-to-deliver' to me when the stock moons.
0 · Reply
ap20
ap20 Feb. 3 at 10:57 PM
$MLTX There is no way Creisi is making this stuff up. If there is any chance he was, he would have been in Hollywood writing and producing block buster movies years ago and a billionaire. This has more twists and surprising turns than the Daytona 500.
2 · Reply
Bigbadjohn89
Bigbadjohn89 Feb. 3 at 10:19 PM
$MLTX AI knows my priorities
2 · Reply
maildriver
maildriver Feb. 3 at 10:15 PM
$MLTX No worries, Creisi will be back in a couple of days when the share price is 14 with some news about a buyout being rejected at 80 a share but just hold on it will pay off in the long run.
3 · Reply
Latest News on MLTX
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Feb 2, 2026, 8:00 AM EST - 1 day ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 27, 2026, 7:30 AM EST - 7 days ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Jan 23, 2026, 7:30 AM EST - 11 days ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

Jan 9, 2026, 8:15 AM EST - 25 days ago

MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

Jan 8, 2026, 2:06 PM EST - 26 days ago

MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

Dec 15, 2025, 10:46 AM EST - 7 weeks ago

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 11, 2025, 10:08 AM EST - 7 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 11, 2025, 8:54 AM EST - 7 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 8, 2025, 1:23 PM EST - 2 months ago

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Stock Picks From Seeking Alpha's November 2025 New Analysts

Dec 8, 2025, 9:00 AM EST - 2 months ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 5, 2025, 8:18 AM EST - 2 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

Dec 5, 2025, 8:06 AM EST - 2 months ago

MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

Dec 4, 2025, 3:01 PM EST - 2 months ago

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

Dec 4, 2025, 9:00 AM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 3, 2025, 7:46 AM EST - 2 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

Dec 2, 2025, 5:29 PM EST - 2 months ago

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

CPTN

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Dec 1, 2025, 5:52 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 3:18 PM EST - 2 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

Dec 1, 2025, 12:26 PM EST - 2 months ago

Voya MidCap Opportunities Strategy Q3 2025 Portfolio Review

APP FIX KTOS TW VRSK

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 30, 2025, 7:45 AM EST - 2 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

Nov 28, 2025, 5:50 PM EST - 2 months ago

MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

Nov 27, 2025, 2:15 PM EST - 2 months ago

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 24, 2025, 6:08 AM EST - 2 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

MoonLake: Ignore The Panic, Catch The Upside

Nov 18, 2025, 12:33 AM EST - 2 months ago

MoonLake: Ignore The Panic, Catch The Upside

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 2 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 8:15 AM EST - 3 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 10, 2025, 6:06 AM EST - 3 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:11 AM EST - 3 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 5, 2025, 7:00 AM EST - 3 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Nov 1, 2025, 7:08 AM EDT - 3 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Oct 28, 2025, 9:51 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

JT4CashMoney
JT4CashMoney Feb. 4 at 1:44 AM
$MLTX just saw this new positive article in MoonLake: https://www.marketbeat.com/originals/biotech-breakout-moonlake-up-30-on-fda-wins/#google_vignette
2 · Reply
GEEK102
GEEK102 Feb. 4 at 1:37 AM
$MLTX might cash out and throw it on open
0 · Reply
Bigpapa46
Bigpapa46 Feb. 4 at 12:20 AM
$MLTX EHSF in Malta runs Feb 4–6, and MoonLake will be presenting several HS talks and posters during the conference. Sessions usually start around 8:30am Malta time, which is about 2:30am Eastern / 11:30pm Pacific (the night before), so any updates will show up very early in the U.S. It’s a medical conference where top HS doctors and specialists see and discuss the data. How they react matters, because these are the people who actually decide how new treatments get used in the real world. So tonight at 11:30pm pacific it kicks off!
0 · Reply
JoeBio
JoeBio Feb. 4 at 12:05 AM
$MLTX MoonLake has not announced any public release date for 48‑week VELA data, but based on the trial timelines and the Week‑16 readout (September 2025), the earliest realistic window for 48‑week data is mid‑to‑late 2026, with the most likely timing around Q3 2026. This is because the VELA trials follow a fixed 52‑week treatment period, and companies typically need several months after the last patient visit to clean, lock, and analyze long‑term data.
0 · Reply
Doomsayer1000
Doomsayer1000 Feb. 3 at 11:43 PM
$MLTX bulls don’t what they’re holding. $14 incoming
1 · Reply
Bigpapa46
Bigpapa46 Feb. 3 at 11:06 PM
$MLTX Bigbadjohn89- AI knows mine as well!
1 · Reply
Modern_portholio_theory
Modern_portholio_theory Feb. 3 at 10:58 PM
$MLTX been tracking available shares which can be borrowed on IBKR...tells an interesting picture right now- appears significantly less people are willling to lend out their shares. what does this mean ? I can only suspect it means certain larger holders are not willing to lend out, for optimistic reasons - I would not want an issue with a shortie having a 'failure-to-deliver' to me when the stock moons.
0 · Reply
ap20
ap20 Feb. 3 at 10:57 PM
$MLTX There is no way Creisi is making this stuff up. If there is any chance he was, he would have been in Hollywood writing and producing block buster movies years ago and a billionaire. This has more twists and surprising turns than the Daytona 500.
2 · Reply
Bigbadjohn89
Bigbadjohn89 Feb. 3 at 10:19 PM
$MLTX AI knows my priorities
2 · Reply
maildriver
maildriver Feb. 3 at 10:15 PM
$MLTX No worries, Creisi will be back in a couple of days when the share price is 14 with some news about a buyout being rejected at 80 a share but just hold on it will pay off in the long run.
3 · Reply
perplex
perplex Feb. 3 at 9:41 PM
$MLTX Just to confirm, at the conference they are presenting 48 week VELA data and what else? Anyone else not excited? If they prove Best in Class again then it’s fireworks atleast in the background! This should be our main focus not share price.
3 · Reply
perplex
perplex Feb. 3 at 9:23 PM
$MLTX This is trading like a Chinese penny stock. Short all day then cover end of day. Not forever.
1 · Reply
JT4CashMoney
JT4CashMoney Feb. 3 at 9:05 PM
$MLTX Added 10% today, throughout the day. The risk/reward here is just too tempting. Irrationally down after a positive news update. Own shares and buy the dip.
0 · Reply
goon9074
goon9074 Feb. 3 at 8:54 PM
$MLTX $62.75 52 week high and here we are at $15 and change. yes, this is completely de-risked, clearly.
1 · Reply
slaykween
slaykween Feb. 3 at 8:45 PM
$MLTX drop is tempting but done adding. Now just breathe in and wait.
1 · Reply
Bigpapa46
Bigpapa46 Feb. 3 at 8:35 PM
$MLTX Just went through and blocked a few people today. Not out of anger, it just gets exhausting trying to explain basic biotech mechanics, valuation models, timelines, and how risk actually works in this sector. it’s about probabilities, pipelines, and weeding through the garbage. Then you take Goon "Phil" that seems to bait me into long winded arguments that always leads to his account being banned. Anyway the board is much cleaner now and it's quiet refreshing to say the least.
1 · Reply
septrading
septrading Feb. 3 at 8:22 PM
$MLTX adding.
0 · Reply
MarkGoldw
MarkGoldw Feb. 3 at 8:14 PM
$MLTX The system is rigged. These shorts sell little by little, and take price down, by end of trading day, They cover in a big piece. There is No any rules to stop these criminals.
1 · Reply
Bigbadjohn89
Bigbadjohn89 Feb. 3 at 8:13 PM
$MLTX Only 150k shares left to borrow
1 · Reply
Felo254
Felo254 Feb. 3 at 7:58 PM
$MLTX The entire market is a shitshow and folks here are worked up about the current price action. MLTX is a set and forget gem no matter the day to day share price. Retail has near zero control of the price. MMs, Tutes, and algos will take the price wherever they want and there’s nothing we can do about it. Everybody relax, buckle up, and wait for the inevitable news drop that will send this to the sky. All about patience here!
0 · Reply
DerekVtx
DerekVtx Feb. 3 at 7:55 PM
$MLTX Fast track approval yesterday, HC Wainright gives is a Buy rating with a $32 target price.....and yet we are down. Very strange.
0 · Reply
Arf28
Arf28 Feb. 3 at 7:54 PM
$MLTX just to get back to where we were after fda ($20). We need to gain over 30%… WTF. Does anyone think there are any substantial events that could take place in the next 60 days to drive share price north of 20 again? We got positive FDA and fast track and still can’t budge!
1 · Reply